In the April 2023 issue of Transfusion Medicine and Hemotherapy, Strengers reviewed future challenges for plasma-derived medicinal products. The review nicely describes the current situation of the global plasma market and its impact on the supply of plasma-derived medicinal product for treatment of patients suffering from immunodeficiency, deficiencies of coagulation factor, inhibitors, etc. [1]. As most source plasma is collected in the USA, intensive national donor campaigns and recruitment programs are necessary to increase plasma collections outside the USA, thereby reducing dependency on international supply chains [2].

Personalized plasmapheresis is an approach to optimize the donation volume without compromising donor safety. Studies from the USA and Germany showed that intensified plasmapheresis is feasible and safe provided that the donor is closely monitored [3‒5]. National guidelines allow for a default donation volume based on donor’s body weight. In Table 1 of Strengers’ review, we noticed that the body weight and the donation volume were not correctly cited for German and US donors.

  • German donors weighing 60 to <70 kg are allowed to donate 750 mL plasma [6].

  • US donors weighting more than 174 lbs are allowed to donate 880 mL plasma [7].

Choosing the correct donation volume based on donors’ body weight is of utmost importance to avoid or reduce adverse donation-associated events.

The authors are employees at Octapharma Plasma GmbH.

No funding was received.

R.M. drafted the manuscript. All authors critically reviewed, revised, and approved the final version of the manuscript.

1.
Strengers
PFW
.
Challenges for plasma-derived medicinal products
.
Transfus Med Hemother
.
2023
;
50
(
2
):
116
22
.
2.
Prevot
J
,
Jolles
S
.
Global immunoglobulin supply: streaming towards the iceberg
.
Curr Opin Allergy Clin Immunol
.
2020
;
20
(
6
):
557
64
.
3.
Hartmann
J
,
Ragusa
MJ
,
Burchardt
ER
,
Manukyan
Z
,
Popovsky
MA
,
Leitman
SF
.
Personalized collection of plasma from healthy donors: a randomized controlled trial of a novel technology-enabled nomogram
.
Transfusion
.
2021
;
61
(
6
):
1789
98
.
4.
Moog
R
,
Laitinen
T
,
Taborski
U
.
Safety of plasmapheresis in donors with low IgG levels: results of a prospective, controlled multicentre study
.
Transfus Med Hemother
.
2022
;
49
(
5
):
271
9
.
5.
Taborski
U
,
Laitinen
T
.
Donor safety in an individualized plasmapheresis program - results of an interim analysis
.
Transfus Apher Sci
.
2022
;
61
(
5
):
103446
.
6.
Guidelines for the collection of blood components and the usage of blood products (hemotherapy)
Cologne
Deutscher Ärzteverlag
2017
.
7.
Volume limits - automated collection of source plasma. Received by all registered establishments. U.S. Food & drug administration
. www.fda.gov/media/70951/download (Accessed August 17, 2020).